The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prospective trial of apalutamide and abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - American Association for Cancer Research; AstraZeneca; Aveo; Axess Oncology; Bayer; Eisai; EMD Serono; Exelixis; IDEOlogy Health; Janssen Oncology; Medscape; Merck; Millennium Medical Publishing; Myovant Sciences; Nektar; Novartis; OncLive; Pfizer; Propella Therapeutics; Sanofi; Seagen; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Novartis; Pfizer; Physicans' Education Resource; Propella Therapeutics; RevHealth; Sanofi; Xcures
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Expert Testimony - Exelixis
Travel, Accommodations, Expenses - Bayer; Exelixis; Novartis; Pfizer
 
Susan Halabi
Employment - ASCO
Honoraria - AVEO; Bristol-Myers Squibb; Janssen; Sanofi
 
Mark T. Fleming
Employment - Virginia Oncology Associates
Leadership - US Oncology
Consulting or Advisory Role - Dendreon; Janssen Oncology
Speakers' Bureau - Genentech; Janssen Oncology
Travel, Accommodations, Expenses - Genentech; Medivation/Astellas
 
Elisabeth I. Heath
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Caris Life Sciences; Genzyme; Janssen; Johnson & Johnson/Janssen; Sanofi; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Janssen; Sanofi; Seagen
Speakers' Bureau - Sanofi
Research Funding - Agensys (Inst); AIQ Solutions (Inst); Arvinas (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); BioXCel therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calibr (Inst); Calithera Biosciences (Inst); Caris Life Sciences (Inst); Celgene (Inst); Celldex (Inst); Champions Oncology (Inst); Corcept Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Curemeta (Inst); Daiichi Sankyo Inc. (Inst); Dendreon (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Esanik (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fortis (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Inovio Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Merck (Inst); Merck Sharp & Dohme (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Modra Pharmaceuticals (Inst); Novartis (Inst); Oncolys BioPharma (Inst); Pellficure (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Pfizer (Inst); Pharmacyclics (Inst); Plexxikon (Inst); POINT Biopharma (Inst); Roche (Inst); Seagen (Inst); Synta (Inst); Tokai Pharmaceuticals (Inst); Zenith Epigenetics (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
Other Relationship - Caris Centers of Excellence
 
Ronald F. Tutrone
Employment - Chesapeake Urology
Stock and Other Ownership Interests - Compass Therapeutics; GlaxoSmithKline; Myovant Sciences; Novartis; Nymox; Veru
Consulting or Advisory Role - Exosome Diagnostics; Myovant Sciences; Novartis; Nymox
Speakers' Bureau - Exosome Diagnostics; Medivation/Astellas; Pfizer
Research Funding - Advantagene (Inst); Bayer (Inst); Dendreon (Inst); Exosome Diagnostics (Inst); Genomic Health (Inst); Janssen Oncology (Inst); MDxHealth (Inst); Medivation/Astellas (Inst); Merck (Inst); POINT Biopharma (Inst); Veru (Inst)
 
Linda Sutton
No Relationships to Disclose
 
Young E. Whang
Consulting or Advisory Role - Janssen Research & Development
Research Funding - Arvinas (Inst); Clovis Oncology (Inst)
 
Brian E. Lewis
No Relationships to Disclose
 
Michael Sandon Humeniuk
No Relationships to Disclose
 
William R. Berry
Consulting or Advisory Role - AstraZeneca; Blue Earth Diagnostics; Merck
Speakers' Bureau - Dendreon
Research Funding - Merck (Inst)
 
Michael Roger Harrison
Honoraria - Exelixis
Consulting or Advisory Role - AVEO; Exelixis; Sanofi
Speakers' Bureau - Eisai; Exelixis; Pfizer/Myovant
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Propella Therapeutics (Inst); Seagen (Inst)
 
Julia Hurrelbrink
No Relationships to Disclose
 
Kellie Shobe
No Relationships to Disclose
 
Julia Rasmussen
Research Funding - Flatiron Health
 
Monika Anand
No Relationships to Disclose
 
Marco Reyes-Martinez
Travel, Accommodations, Expenses - Exelixis
 
Lauren Howard
Research Funding - Bayer (Inst); Diasorin (Inst); Ferring (Inst); LungLife AI (Inst); MDxHealth (Inst); Merck (Inst); Myriad Genetics (Inst); Sanofi (Inst)
 
Steven R. Patierno
Leadership - Curaleaf; Theralogix
Stock and Other Ownership Interests - Curaleaf
Consulting or Advisory Role - Curaleaf; Theralogix
Research Funding - AstraZeneca
Patents, Royalties, Other Intellectual Property - Patents and Patents Pending
 
Jennifer A Freedman
No Relationships to Disclose
 
Andrew J. Armstrong
Consulting or Advisory Role - Astellas Scientific and Medical Affairs Inc; AstraZeneca; Bayer; Bristol-Myers Squibb; Epic Sciences; Exelixis; FORMA Therapeutics; GoodRx; IDEAYA Biosciences; Janssen; Merck; Myovant Sciences; Novartis; Pfizer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); FORMA Therapeutics (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Astellas Scientific and Medical Affairs Inc